Skip to main content
SpringerLink
Log in

IV immunoglobulin well tolerated in chronic inflammatory demyelinating polyneuropathy

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The ProCID study was funded by Octapharma Pharmazeutika Produktionsges.m.b.H., Austria.

Reference

  • Cornblath DR, et al. Safety and Tolerability of Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy: Results of the ProCID Study. Drug Safety : 28 Jun 2023. Available from: URL: http://doi.org/10.1007/s40264-023-01326-z

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

IV immunoglobulin well tolerated in chronic inflammatory demyelinating polyneuropathy. Reactions Weekly 1965, 10 (2023). https://doi.org/10.1007/s40278-023-42978-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-42978-4

Search

Navigation